ArticleFrontiers in immunology2026
Genome-wide gene expression analysis suggests an important regulatory role of lncRNAs in primary Sjögren's syndrome.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary Sjögren's syndrome (pSS) is a common autoimmune disease, with the minor salivary gland (MSG) being the main affected tissue; however, its pathogenesis remains unclear. Although changes in long noncoding RNA (lncRNA) expression have been reported in pSS, their biological functions are uncertain, despite the regulatory roles suggested. Therefore, it would be meaningful to systematically investigate the gene expression of lncRNAs in pSS for their regulatory roles and possible contribution to the disease development. Methods: Deep stranded total transcriptome sequencing was performed on MSG samples from 92 patients with pSS and 34 non-Sjögren's syndrome (non-SS) controls. Differentially expressed genes between pSS and non-SS were identified, and a genome-wide competing endogenous RNA (ceRNA) network was constructed based on shared miRNA binding sites and gene-expression correlations. The regulatory roles of lncRNAs in dysregulated pathways in pSS were assessed by examining expression changes of interacting lncRNAs and coding genes. Results: Genome-wide coding and noncoding gene expression correlation analysis suggests the regulatory function of lncRNAs in pSS. LncRNA could regulate coding gene expression via ceRNA mechanisms. The genome-wide ceRNA network comprising 3,035 lncRNAs and 10,838 coding genes was constructed. Eight lncRNAs were predicted to play essential roles on coding gene expression changes in pSS. The regulatory effect for three of the eight key lncRNAs-BISPR, LINC00926, and HCP5-were validated by Discussion: Systematic analysis of coding and lncRNA expression in MSG samples suggests a genome-wide regulatory role for lncRNAs in pSS. We constructed, for the first time, a genome-wide ceRNA network. This ceRNA network can be used to infer lncRNA functions based on their interacting coding genes. The gene regulatory roles of three lncRNAs were validated. Our study suggests that lncRNAs contribute significantly to coding gene expression changes in pSS via ceRNA mechanisms, and the identified regulatory lncRNA candidates could be useful for diagnosis, sub-classification, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.